Back

Design of ODYSSEY-HCM: a phase 3 randomized placebo-controlled study to assess the efficacy and safety of mavacamten in patients with nonobstructive hypertrophic cardiomyopathy

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Myocardial disease - clinical 9 Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Professor Iacopo Olivotto

University of Florence, Florence (Italy)

6 More presentations in this session

Presentation thumbnail
Are sodium-glucose co-transporter 2 inhibitors safe in hypertrophic cardiomyopathy?
Doctor V. Biletska (Kharkiv, UA)
Abstract Slides Video
Presentation thumbnail
Genetic testing in hypertrophic cardiomyopathy: for all or just selected patients?
Doctor A. Fonseca Vazao (Leiria, PT)
Abstract Slides Video
Presentation thumbnail
Hypertrophic cardiomyopathy phenotype and the importance of systemic inflammation
Doctor I. Miranda (Amadora, PT)
Abstract Slides Video
Presentation thumbnail
Could we use cardiopulmonary exercise test to distinguish hypertrophic cardiomyopathy from Fabry disease? New insights from Italy
Doctor F. Re (Roma, IT)
Abstract Slides Video
Presentation thumbnail
Is the mortality of chronic chagas cardiomyopathy higher than cardiomyopathy due to other etiologies? A systematic review and meta-analysis
Doctor L. Echeverria (Floridablanca, CO)
Abstract Slides Video

Access the full session

Session thumbnail
Myocardial disease - clinical 9

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Cardiac biomarkers on mavacamten in nonobstructive HCM: Sub-study of the ODYSSEY-HCM trial
thumbnail
Congress Presentation
Long-term efficacy of mavacamten on health status in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: results from long-term extension of the EXPLORER-CN trial
thumbnail
Congress Presentation
Real-world health status changes with mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) - Early findings from COMPASS-HCM

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources